StatOrigin open statistical archive
Live Industries Statistics Regions Rankings Reports Compare Sources

Publisher · 346 documents · 346 figures

ClinicalTrials.gov (U.S. National Library of Medicine)

346 verified figures from 346 publications by ClinicalTrials.gov, a government body. Every figure links to the document and sentence it came from.

JSON Official site Cite and reuse
Data points
346
Documents
346
Indicators
146
Regions
3
Publisher type
Government

Documents used

Every publication we have taken a number from, with the date we read it and the link status at that time.

Document Type Retrieved Link Data points
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in myasthenia gravis, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic lupus erythematosus / lupus nephritis, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic sclerosis, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in vasculitis, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in alcohol or substance use, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in chronic kidney disease, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in heart failure or cardiovascular disease, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in mash / nash, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in obesity or overweight, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in type 2 diabetes, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited eye disease, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited liver and metabolic disease, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified in crohn's disease, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified in ulcerative colitis, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in advanced solid tumours (basket), with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in colorectal cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in non-small cell lung cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in pancreatic cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in gastric, oesophageal or colorectal cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in liver or biliary cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in multiple myeloma, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in any country Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in breast cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in kidney cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in lung cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in neuroendocrine tumours, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in prostate cancer, with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional drug or biologic studies in Alzheimer's disease, any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes), any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents), any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer, any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease, any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product, any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified, any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others), any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: All interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy, any start date, as registered on 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of ANGPTL3 (zodasiran, solbinsiran) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of APOC3 (olezarsen, plozasiran) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Actinium-225 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Adagrasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Agitation and psychosis in Alzheimer's (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Allogeneic or universal (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Amivantamab (EGFR x MET) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Amycretin (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Anti-TL1A antibodies (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Anti-amyloid antibodies (all) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Anti-integrin (vedolizumab and others) (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of BCMA x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of BCMA-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of BL-B01D1 (EGFR x HER3 bispecific ADC) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Base editing (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CAR-NK (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CD19-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CD20 x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Cadonilimab (PD-1 x CTLA-4) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of CagriSema / cagrilintide (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Daraxonrasib (pan-RAS) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Datopotamab deruxtecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Disitamab vedotin (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Divarasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Donanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Enfortumab vedotin (Nectin-4) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Ex vivo edited stem cells (sickle cell, thalassaemia) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of GLP-1 receptor agonists (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Garsorasib, fulzerasib and glecirasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Gene-edited CAR-T or TCR-T (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of IL-23 p19 antibodies (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of In vivo liver editing (LNP) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Inclisiran (PCSK9 siRNA) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Ivonescimab (PD-1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of JAK inhibitors (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of KRAS G12D-directed agents (inhibitors, degraders, vaccines, cell therapies) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Lead-212 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Lecanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Lp(a) lowering (olpasiran, lepodisiran, zerlasiran, pelacarsen, muvalaplin) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Lutetium-177 agents (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of MariTide (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Mazdutide (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Obefazimod (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Obicetrapib (CETP) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Olomorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Oral IL-23 receptor peptide (icotrokinra) (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Oral PCSK9 inhibitors (enlicitide, AZD0780) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Orforglipron (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of PD-(L)1 x VEGF bispecifics (all) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of PSMA-targeted (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Pumitamig / BNT327 (PD-L1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Radium-223 (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Retatrutide (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of S1P modulators (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of SHR-A1811 / trastuzumab rezetecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Sacituzumab govitecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Sacituzumab tirumotecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Semaglutide (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Somatostatin-receptor-targeted (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Sotorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of T-cell engagers (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of TTR silencers (vutrisiran, patisiran, eplontersen, nucresiran) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Tarlatamab (DLL3 x CD3) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Tau-targeted therapies (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Tirzepatide (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Trastuzumab deruxtecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1
ClinicalTrials.gov study count: Interventional studies of Trontinemab (brain shuttle) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Licence: Public domain Dataset 27 Sep 2026 Reachable 1

Measures from this publisher

Every measure taken from ClinicalTrials.gov, with its latest value and trend. Each value opens its record.

Market size and output 4

Cardiometabolic RNA and next-generation lipid drug trial starts Global · 1 Jan 2023 to 27 Sep 2026 128 ClinicalTrials.gov 21 records
Active cardiometabolic RNA and next-generation lipid drug trials Global · as of 27 Sep 2026 90 ClinicalTrials.gov 1 record
Phase 3 cardiometabolic RNA and next-generation lipid drug trials Global · as of 27 Sep 2026 103 ClinicalTrials.gov 1 record
Registered interventional cardiometabolic RNA and next-generation lipid drug trials Global · as of 27 Sep 2026 237 ClinicalTrials.gov 1 record

Other measures 142

Alzheimer's disease drug trial starts Global · 1 Jan 2023 to 27 Sep 2026 269 ClinicalTrials.gov 21 records
Antibody-drug conjugate trial starts Global · 1 Jan 2023 to 27 Sep 2026 1,225 ClinicalTrials.gov 21 records
Autoimmune cell therapy and T-cell engager trial starts Global · 1 Jan 2023 to 27 Sep 2026 300 ClinicalTrials.gov 21 records
Gene editing trial starts Global · 1 Jan 2023 to 27 Sep 2026 133 ClinicalTrials.gov 21 records
GLP-1, incretin multi-agonist and amylin trial starts Global · 1 Jan 2023 to 27 Sep 2026 798 ClinicalTrials.gov 21 records
Inflammatory bowel disease drug trial starts Global · 1 Jan 2023 to 27 Sep 2026 373 ClinicalTrials.gov 21 records
Show 136 more measures

76 further measures are in the CSV download.

146 measures. Each name opens the full series; each value opens the record with its source quote.

Cite this page

Data on this page is published under CC BY 4.0. Credit ClinicalTrials.gov (U.S. National Library of Medicine) as the original publisher; each record page carries its own citation.

ClinicalTrials.gov (U.S. National Library of Medicine). Retrieved from StatOrigin: https://statorigin.org/sources/clinicaltrials-gov

This organisation as JSON

Related

Industries using this source

Go further

Last verified 27 September 2026. Link status is rechecked weekly.